Skip to main content
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc — Investor Relations & Filings

Ticker · PTGX ISIN · US74366E1029 US Manufacturing
Open in API
Filings indexed 641 across all filing types
Latest filing 2020-05-07 Earnings Release
Country US United States of America
Listing US PTGX

About Protagonist Therapeutics, Inc

https://www.protagonist-inc.com/

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of peptide-based new chemical entities. The company utilizes its proprietary technology platform to engineer novel oral and injectable peptide therapeutics. Its development pipeline is focused on creating treatments for rare and prevalent diseases, particularly in the areas of hematology and gastroenterology, addressing significant unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 7, 2020, reporting the company's financial results for the quarter ended March 31, 2020. It includes references to press releases about first quarter financial results and a corporate update, as well as initial Phase 2 clinical trial results. The document is relatively short (4688 characters) and primarily serves as a current report to announce these events and furnish press releases as exhibits. It does not contain detailed financial statements or comprehensive financial analysis itself, but rather points to press releases and updates. This aligns with the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly financial results and key highlights. Therefore, the appropriate classification is Earnings Release (ER).
2020-05-07 English
FORM 4 SUBMISSION
Director's Dealing
2020-05-01 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement and additional materials related to the Annual Meeting of Stockholders. It includes information about voting, director nominations, and ratification of the independent auditor. The text explicitly mentions it is a proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934 and includes voting instructions and meeting details. This type of document is classified as Proxy Solicitation & Information Statement (PSI). The document length is 6663 characters, which is sufficient to contain substantive proxy materials rather than just an announcement. Therefore, the correct classification is PSI.
2020-04-16 English
DEF 14A
Proxy Solicitation & Information Statement
2020-04-16 English
FORM 4 SUBMISSION
Director's Dealing
2020-04-08 English
FORM 4 SUBMISSION
Director's Dealing
2020-03-23 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.